Nanoparticle-mediated gene delivery to tumour neovasculature

A.R. Reynolds; S.M. Moghimi; K. Hodivala-Dilke

doi:doi:10.1016/S1471-4914(02)00004-7

Nanoparticle-mediated gene delivery to tumour neovasculature

A.R. Reynolds, S.M. Moghimi, K. Hodivala-Dilke

University of Brighton

Research output: Contribution to journal › Article › peer-review

Abstract

The αvβ3 integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of αvβ3-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.

Original language	English
Pages (from-to)	2-4
Number of pages	3
Journal	Trends in molecular medicine
Volume	9
Issue number	1
DOIs	https://doi.org/doi:10.1016/S1471-4914(02)00004-7
Publication status	Published - Jan 2003

Access to Document

doi:10.1016/S1471-4914(02)00004-7Licence: Unspecified

http://dx.doi.org/10.1016/S1471-4914(02)00004-7Licence: Unspecified

Cite this

@article{8f71bbf2aa034b41b2999a09240fb221,

title = "Nanoparticle-mediated gene delivery to tumour neovasculature",

abstract = "The αvβ3 integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of αvβ3-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.",

author = "A.R. Reynolds and S.M. Moghimi and K. Hodivala-Dilke",

year = "2003",

month = jan,

doi = "doi:10.1016/S1471-4914(02)00004-7",

language = "English",

volume = "9",

pages = "2--4",

journal = "Trends in molecular medicine",

issn = "1471-4914",

number = "1",

}

TY - JOUR

T1 - Nanoparticle-mediated gene delivery to tumour neovasculature

AU - Reynolds, A.R.

AU - Moghimi, S.M.

AU - Hodivala-Dilke, K.

PY - 2003/1

Y1 - 2003/1

N2 - The αvβ3 integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of αvβ3-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.

AB - The αvβ3 integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of αvβ3-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.

U2 - doi:10.1016/S1471-4914(02)00004-7

DO - doi:10.1016/S1471-4914(02)00004-7

M3 - Article

SN - 1471-4914

VL - 9

SP - 2

EP - 4

JO - Trends in molecular medicine

JF - Trends in molecular medicine

IS - 1

ER -

Nanoparticle-mediated gene delivery to tumour neovasculature

Abstract

Access to Document

Fingerprint

Cite this